{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-349193","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2026-08-13T20:11:08+00:00","discovered_at":"2026-08-13T20:13:00.258618+00:00","generated_at":"2026-08-13T20:13:24.929876+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Invivyd Q2 2026 revenue up 21% to $14.3M; net loss widens to $44.4M; PEMGARDA EUA termination notice","bullets":["Q2 2026 PEMGARDA net product revenue $14.3M, up 21% YoY from $11.8M.","Net loss $44.4M vs $14.7M; EPS -$0.14 vs -$0.12; R&D spend $29.4M vs $9.6M.","Cash $160.1M; runway through DECLARATION data readout and potential VYD2311 launch.","Received 12-month notice of PEMGARDA EUA termination in July 2026; in dialogue with FDA.","DECLARATION enrollment complete, top-line data later Q3 2026; LIBERTY fully dosed, top-line late Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-349193","json":"https://secwatch.observer/filing/0001193125-26-349193.json","markdown":"https://secwatch.observer/filing/0001193125-26-349193.md","text":"https://secwatch.observer/filing/0001193125-26-349193.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312526349193/0001193125-26-349193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312526349193/ivvd-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:13:24.929876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}